All News

The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.

Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.